...Hello, colleagues. I am Sunao Manabe, Executive Chairperson and CEO of Daiichi Sankyo. Welcome to our Science and Technology Day. With the growing DXd ADC pipeline, we understand that many stakeholders are very interested in our technology as well as our ADC manufacturing and supply plan. So we have renamed this annual IR event, Science and Technology Day of this year. When I look back on this year, one of our big accomplishments was the DESTINY-Breast06 study presented at ASCO in June. Based on the data, we anticipate to further redefine the classification and treatment of metastatic breast cancer with a new use of ENHERTU for patients with unresectable or metastatic hormone receptor positive, HER2-low and HER2-ultralow breast cancer. We believe that ENHERTU will continue to change the treatment of paradigm for certain patients with breast cancer and broaden the number of people who may be eligible for a HER2-directed medicine. Recently, we announced that Daiichi Sankyo and AstraZeneca...
